Sarcoma Oncology Research Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Sarcoma Oncology Research Center sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 5 currently recruiting 1 completed early-phase tilt upper quartile by trial count

Sarcoma Oncology Research Center: 8 sponsored US clinical trials, 5 recruiting.

Sarcoma Oncology Research Center sponsors 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sarcoma, with 3 trials.

Upper-quartile sponsor footprint

Sarcoma Oncology Research Center sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 2

Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors

NCT07671534
RECRUITING Phase 2

Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma

NCT04535271
RECRUITING Phase 2

GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma

NCT04535713
RECRUITING Phase 2

Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

NCT03886311
RECRUITING Phase 1

SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

NCT03138161
ACTIVE NOT RECRUITING Phase 2

SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma

NCT03778996
ACTIVE NOT RECRUITING Phase 1

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

NCT04165330
COMPLETED Phase 1

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

NCT03190174

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 5

Therapeutic Areas

Sarcoma 3
Sarcoma, Ewing 1
Metastatic Soft Tissue Sarcoma 1
Advanced Soft Tissue Sarcoma 1
Soft Tissue Sarcoma 1
Solid Tumor, Adult 1
Leiomyosarcoma 1
Small-cell Lung Cancer 1
Non-Small Cell Lung Cancer 1

What is open in the Sarcoma Oncology Research Center pipeline

5 recruiting of 8 indexed (63% open); 1 completed (13%).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Sarcoma (3 trials), 8 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Sarcoma Oncology Research Center: open-pipeline peers nationwide

Peers matched on 8 registered trials and 63% open enrollment, not the therapeutic-area sidebar.

Sarcoma Oncology Research Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%20%40%60%80% Total trials Recruiting share Sarcoma Oncology Research CenterAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Canadian Cancer Trials GroupCellSight TechnologiesCook Children's Health Care SystemNurix Therapeutics
Sarcoma Oncology Research Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Sarcoma Oncology Research Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 63% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Sarcoma Oncology Research Center page

8 registered trials is a research-attention snapshot, not an endorsement of Sarcoma Oncology Research Center or any single study.

  • 5 of Sarcoma Oncology Research Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Sarcoma is the condition Sarcoma Oncology Research Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sarcoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Sarcoma Oncology Research Center pipeline card: 8 registered trials from official public datasets.Report a data error.